Compared side by side
Retatrutide vs mazdutide: how they differ
The short answer
Both add the glucagon receptor to GLP-1, and the glucagon arm adds energy expenditure (shown so far in mice); retatrutide adds GIP as a third target. Mazdutide, from Innovent and Eli Lilly, was approved in China in 2025 and isn’t FDA-approved; retatrutide isn’t approved yet. In their own trials, a 9 mg dose of mazdutide averaged about 17% weight loss at 60 weeks (GLORY-2), and retatrutide’s top dose about 25–28% at 80 weeks in phase 3.
Side by side
| Compared | Retatrutide | Mazdutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | LY3437943 | IBI362, LY3305677, Xinermei |
| What it is | The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). | A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. |
| How it works | Triple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one. | Once-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups. |
| Commonly reported | Appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet. | Strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few. |
| Studied range | Research range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation. | Research range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~6 days (measured in early trials in people) | ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes) |
| Route | SubQ injection | SubQ injection |
| Typical run | Phase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration. | Used continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain | Nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux |
- Category
- RetatrutideMetabolic & GLP-1
- MazdutideMetabolic & GLP-1
- Also known as
- RetatrutideLY3437943
- MazdutideIBI362, LY3305677, Xinermei
- What it is
- RetatrutideThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).
- MazdutideA once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved.
- How it works
- RetatrutideTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.
- MazdutideOnce-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups.
- Commonly reported
- RetatrutideAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.
- MazdutideStrong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.
- Studied range
- RetatrutideResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.
- MazdutideResearch range: 2–6 mg, starting dose 2 mg. Studied in research — not a recommendation.
- How often
- RetatrutideWeekly
- MazdutideWeekly
- Half-life
- Retatrutide~6 days (measured in early trials in people)
- Mazdutide~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes)
- Route
- RetatrutideSubQ injection
- MazdutideSubQ injection
- Typical run
- RetatrutidePhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.
- MazdutideUsed continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it.
- Evidence
- RetatrutideEstablished: clinical trials or FDA-approved use exists
- MazdutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- RetatrutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain
- MazdutideNausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Retatrutide
- Day 1–28 · 2 mg Triple-agonist is kicking in
- Day 29–84 · 4 mg Dose-response steepens
- Day 60+ · 9 mg Watch for dysesthesia at higher doses
- Day 84+ This is a maintenance medication, not a course
- Day 85–168 · 8 mg Higher steps: strong satiety
- Day 169–336 No plateau yet at week 48
- Day 337–476 Phase 3 territory: the headline numbers
Mazdutide
- Day 1–28 · 2 mg Appetite first, scale later
- Day 29–56 · 4 mg A maintenance dose, not just a step
- Day 57–224 · 4 mg Holding at 4 mg
- Day 57–224 · 6 mg The top labelled dose
- Day 225–336 Weeks 32 to 48: still moving, more slowly
- Day 337+ A maintenance medication, not a course
Questions people ask
How long do retatrutide and mazdutide last?
The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes).
How often are retatrutide and mazdutide taken?
Retatrutide: weekly. Route: SubQ injection. Mazdutide: weekly. Route: SubQ injection.
How are retatrutide and mazdutide dosed in research?
The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. The research range for mazdutide is 2–6 mg, with a 2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of retatrutide and mazdutide?
For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For mazdutide: nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness, acid reflux.